The new COO of Enhance3D Genomics, Hazel Jones, has over 10 years of senior leadership experience in oncology research. She has significant expertise in working across functions to develop effective partnerships aligned with complex operational procedures. This delivers clear business objectives and maximises the outcome of partnerships to advance disease diagnosis and treatments for patients. Prior to joining Enhanc3D Genomics, Jones held various roles within AstraZeneca, including Executive Product Director of Clinical Data, and Head of Business Planning and Operations in Oncology R&D. She was also previously Head of Combination Therapies at Cancer Research UK. Jones holds a BSc in Pharmacology and completed her PhD in Biochemistry at the University of Leeds.

Following a £10 million Series A financing in October 2022, the appointmentof Hazel Jones is the next step in the Company’s drive to broaden the application of its technology and secure strategic collaboration agreements with pharmaceutical partners.

Enhanc3D Genomics has established a genome-wide 3D-sequencing platform (GenLink3D™) that can globally connect enhancer regions and GWAS (genome-wide association study) risk loci to their core target genes. The company is located at St John’s Innovation Park in Cambridge (UK).

Dr Debora Lucarelli, Chief Executive Officer, Enhanc3D Genomics, commented: “Hazel’s in-depth experience will be invaluable to the next stages of our development, as we seek to establish strategic partnerships to develop our extensive database of candidate therapeutic targets and disease biomarkers. With a proven ability to operate autonomously across large-scope projects, combined with a deep understanding of the pharmaceutical development process and a people-centric leadership approach, Hazel will play a central role in driving significant operational change to create maximum value for Enhanc3D Genomics’ stakeholders. I am delighted to welcome Hazel to the team.”